ID   ENPP7_HUMAN             Reviewed;         458 AA.
AC   Q6UWV6; Q6ZTS5; Q8IUS8;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   25-MAY-2022, sequence version 4.
DT   18-JUN-2025, entry version 169.
DE   RecName: Full=Ectonucleotide pyrophosphatase/phosphodiesterase family member 7;
DE            Short=E-NPP 7;
DE            Short=NPP-7;
DE            EC=3.1.4.12 {ECO:0000269|PubMed:12671034, ECO:0000269|PubMed:12885774, ECO:0000269|PubMed:15205117, ECO:0000269|PubMed:28292932};
DE   AltName: Full=Alkaline sphingomyelin phosphodiesterase;
DE   AltName: Full=Intestinal alkaline sphingomyelinase {ECO:0000303|PubMed:12671034, ECO:0000303|PubMed:12885774};
DE            Short=Alk-SMase {ECO:0000303|PubMed:12885774, ECO:0000303|PubMed:28292932};
DE   Flags: Precursor;
GN   Name=ENPP7 {ECO:0000312|EMBL:AAH41453.2, ECO:0000312|HGNC:HGNC:23764};
GN   ORFNames=UNQ3077/PRO9912;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAP69661.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 137-151; 239-248; 256-271
RP   AND 313-326, FUNCTION, IDENTIFICATION BY MASS SPECTROMETRY, CATALYTIC
RP   ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Colon {ECO:0000269|PubMed:12885774}, Kidney
RC   {ECO:0000269|PubMed:12885774}, Small intestine
RC   {ECO:0000269|PubMed:12885774}, and Stomach
RC   {ECO:0000269|PubMed:12885774};
RX   PubMed=12885774; DOI=10.1074/jbc.m305437200;
RA   Duan R.-D., Bergman T., Xu N., Wu J., Cheng Y., Duan J., Nelander S.,
RA   Palmberg C., Nilsson A.;
RT   "Identification of human intestinal alkaline sphingomyelinase as a novel
RT   ecto-enzyme related to the nucleotide phosphodiesterase family.";
RL   J. Biol. Chem. 278:38528-38536(2003).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAQ88985.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:BAC86504.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver {ECO:0000312|EMBL:BAC86504.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:AAH41453.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon {ECO:0000312|EMBL:AAH41453.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5] {ECO:0000305}
RP   PROTEIN SEQUENCE OF 22-36.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [6] {ECO:0000305}
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12671034; DOI=10.1194/jlr.m300037-jlr200;
RA   Duan R.-D., Cheng Y., Hansen G., Hertervig E., Liu J.-J., Syk I.,
RA   Sjostrom H., Nilsson A.;
RT   "Purification, localization, and expression of human intestinal alkaline
RT   sphingomyelinase.";
RL   J. Lipid Res. 44:1241-1250(2003).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=15205117; DOI=10.1152/ajpgi.00190.2004;
RA   Wu J., Liu F., Nilsson A., Duan R.D.;
RT   "Pancreatic trypsin cleaves intestinal alkaline sphingomyelinase from
RT   mucosa and enhances the sphingomyelinase activity.";
RL   Am. J. Physiol. 287:G967-G973(2004).
RN   [8] {ECO:0000305}
RP   MUTAGENESIS OF HIS-353.
RX   PubMed=15016655; DOI=10.1093/carcin/bgh140;
RA   Wu J., Cheng Y., Nilsson A., Duan R.-D.;
RT   "Identification of one exon deletion of intestinal alkaline
RT   sphingomyelinase in colon cancer HT-29 cells and a differentiation-related
RT   expression of the wild-type enzyme in Caco-2 cells.";
RL   Carcinogenesis 25:1327-1333(2004).
RN   [9] {ECO:0000305}
RP   GLYCOSYLATION AT ASN-100; ASN-121; ASN-146; ASN-168 AND ASN-267, AND
RP   MUTAGENESIS OF SER-76; CYS-78; ASN-100; ASN-121; ASN-146; ASN-168 AND
RP   ASN-267.
RX   PubMed=15458386; DOI=10.1042/bj20041455;
RA   Wu J., Hansen G.H., Nilsson A., Duan R.-D.;
RT   "Functional studies of human intestinal alkaline sphingomyelinase by
RT   deglycosylation and mutagenesis.";
RL   Biochem. J. 386:153-160(2005).
RN   [10]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=16255717; DOI=10.1042/bj20051121;
RA   Wu J., Nilsson A., Joensson B.A., Stenstad H., Agace W., Cheng Y.,
RA   Duan R.D.;
RT   "Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-
RT   activating factor by a phospholipase C activity.";
RL   Biochem. J. 394:299-308(2006).
RN   [11]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-146.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [12] {ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 17-433 IN COMPLEX WITH ZINC AND
RP   PHOSPHOCHOLINE, CATALYTIC ACTIVITY, FUNCTION, COFACTOR, GLYCOSYLATION AT
RP   ASN-100; ASN-121; ASN-146; ASN-168 AND ASN-267, AND MUTAGENESIS OF TYR-109;
RP   TYR-166; ARG-271; ARG-343 AND 344-ILE--PHE-348.
RX   PubMed=28292932; DOI=10.1074/jbc.m116.769273;
RA   Gorelik A., Liu F., Illes K., Nagar B.;
RT   "Crystal structure of the human alkaline sphingomyelinase provides insights
RT   into substrate recognition.";
RL   J. Biol. Chem. 292:7087-7094(2017).
CC   -!- FUNCTION: Choline-specific phosphodiesterase that hydrolyzes
CC       sphingomyelin releasing the ceramide and phosphocholine and therefore
CC       is involved in sphingomyelin digestion, ceramide formation, and fatty
CC       acid (FA) absorption in the gastrointestinal tract (PubMed:12671034,
CC       PubMed:12885774, PubMed:15205117, PubMed:16255717, PubMed:28292932).
CC       Also has phospholipase C activity and can also cleave phosphocholine
CC       from palmitoyl lyso-phosphatidylcholine and platelet-activating factor
CC       (PAF) leading to its inactivation (PubMed:12885774, PubMed:16255717).
CC       Does not have nucleotide pyrophosphatase activity (PubMed:12885774).
CC       May promote cholesterol absorption by affecting the levels of
CC       sphingomyelin derived from either diet or endogenous sources, in the
CC       intestinal lumen (By similarity). {ECO:0000250|UniProtKB:Q3TIW9,
CC       ECO:0000269|PubMed:12671034, ECO:0000269|PubMed:12885774,
CC       ECO:0000269|PubMed:15205117, ECO:0000269|PubMed:16255717,
CC       ECO:0000269|PubMed:28292932}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a sphingomyelin + H2O = phosphocholine + an N-acylsphing-4-
CC         enine + H(+); Xref=Rhea:RHEA:19253, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:17636, ChEBI:CHEBI:52639,
CC         ChEBI:CHEBI:295975; EC=3.1.4.12;
CC         Evidence={ECO:0000269|PubMed:12671034, ECO:0000269|PubMed:12885774,
CC         ECO:0000269|PubMed:15205117, ECO:0000269|PubMed:16255717,
CC         ECO:0000269|PubMed:28292932};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19254;
CC         Evidence={ECO:0000269|PubMed:16255717};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         hexadecanoyl-sn-glycerol + phosphocholine + H(+);
CC         Xref=Rhea:RHEA:41119, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75542, ChEBI:CHEBI:295975;
CC         Evidence={ECO:0000269|PubMed:12885774};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41120;
CC         Evidence={ECO:0000305|PubMed:12885774};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = a 1-
CC         O-alkyl-2-acetyl-sn-glycerol + phosphocholine + H(+);
CC         Xref=Rhea:RHEA:63380, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16291, ChEBI:CHEBI:36707, ChEBI:CHEBI:295975;
CC         Evidence={ECO:0000269|PubMed:16255717};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63381;
CC         Evidence={ECO:0000269|PubMed:16255717};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-octadecyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         O-octadecyl-2-acetyl-sn-glycerol + phosphocholine + H(+);
CC         Xref=Rhea:RHEA:63384, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:52450, ChEBI:CHEBI:147296, ChEBI:CHEBI:295975;
CC         Evidence={ECO:0000250|UniProtKB:Q5EZ72};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63385;
CC         Evidence={ECO:0000250|UniProtKB:Q5EZ72};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:28292932};
CC   -!- ACTIVITY REGULATION: Inhibited in a dose dependent manner by ATP,
CC       imidazole, orthovanadate and zinc ion. Not inhibited by ADP, AMP and
CC       EDTA. {ECO:0000269|PubMed:12885774}.
CC   -!- INTERACTION:
CC       Q6UWV6; Q9BYV9: BACH2; NbExp=3; IntAct=EBI-12047821, EBI-1642333;
CC       Q6UWV6; Q08379: GOLGA2; NbExp=3; IntAct=EBI-12047821, EBI-618309;
CC       Q6UWV6; P26371: KRTAP5-9; NbExp=3; IntAct=EBI-12047821, EBI-3958099;
CC       Q6UWV6; Q5JTD7: LRRC73; NbExp=3; IntAct=EBI-12047821, EBI-12003882;
CC       Q6UWV6; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-12047821, EBI-11522433;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12671034,
CC       ECO:0000269|PubMed:15205117}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:12671034, ECO:0000269|PubMed:15205117}. Note=The
CC       catalytic domain is released into the extracellular medium when cells
CC       are treated with trypsin (PubMed:15205117). Localized at the surface of
CC       the microvillar membrane in small intestine enterocytes, and in
CC       endosome-like structures situated beneath the microvillar membrane, and
CC       in Golgi complex (PubMed:12671034, PubMed:12885774).
CC       {ECO:0000269|PubMed:12671034, ECO:0000269|PubMed:12885774,
CC       ECO:0000269|PubMed:15205117}.
CC   -!- TISSUE SPECIFICITY: Detected in the colon (at protein level). Expressed
CC       in the duodenum, jejunum and liver and at low levels in the ileum.
CC       Expression was very low in the esophagus, stomach and colon.
CC       {ECO:0000269|PubMed:12671034, ECO:0000269|PubMed:12885774}.
CC   -!- PTM: N-glycosylated; required for activity and transport to the plasma
CC       membrane. {ECO:0000269|PubMed:15458386, ECO:0000269|PubMed:19159218}.
CC   -!- MISCELLANEOUS: Decreased levels of alkaline sphingomyelin
CC       phosphodiesterase may be associated with colon cancer.
CC       {ECO:0000303|PubMed:12671034, ECO:0000303|PubMed:15016655}.
CC   -!- SIMILARITY: Belongs to the nucleotide pyrophosphatase/phosphodiesterase
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/44055/ENPP7";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY230663; AAP69661.1; -; mRNA.
DR   EMBL; AY358622; AAQ88985.1; -; mRNA.
DR   EMBL; AK126250; BAC86504.1; -; mRNA.
DR   EMBL; BC041453; AAH41453.2; -; mRNA.
DR   CCDS; CCDS11763.1; -.
DR   RefSeq; NP_848638.3; NM_178543.4.
DR   PDB; 5TCD; X-ray; 2.40 A; A=22-433.
DR   PDB; 5UDY; X-ray; 2.60 A; A=22-433.
DR   PDBsum; 5TCD; -.
DR   PDBsum; 5UDY; -.
DR   AlphaFoldDB; Q6UWV6; -.
DR   SMR; Q6UWV6; -.
DR   BioGRID; 130844; 31.
DR   FunCoup; Q6UWV6; 83.
DR   IntAct; Q6UWV6; 27.
DR   STRING; 9606.ENSP00000332656; -.
DR   ChEMBL; CHEMBL6058; -.
DR   SwissLipids; SLP:000000173; -.
DR   GlyCosmos; Q6UWV6; 5 sites, No reported glycans.
DR   GlyGen; Q6UWV6; 8 sites, 14 N-linked glycans (4 sites).
DR   iPTMnet; Q6UWV6; -.
DR   PhosphoSitePlus; Q6UWV6; -.
DR   BioMuta; ENPP7; -.
DR   DMDM; 134047772; -.
DR   jPOST; Q6UWV6; -.
DR   MassIVE; Q6UWV6; -.
DR   PaxDb; 9606-ENSP00000332656; -.
DR   PeptideAtlas; Q6UWV6; -.
DR   ProteomicsDB; 67528; -.
DR   Antibodypedia; 19751; 245 antibodies from 27 providers.
DR   DNASU; 339221; -.
DR   Ensembl; ENST00000328313.10; ENSP00000332656.5; ENSG00000182156.10.
DR   GeneID; 339221; -.
DR   KEGG; hsa:339221; -.
DR   MANE-Select; ENST00000328313.10; ENSP00000332656.5; NM_178543.5; NP_848638.3.
DR   UCSC; uc002jxa.5; human.
DR   AGR; HGNC:23764; -.
DR   CTD; 339221; -.
DR   DisGeNET; 339221; -.
DR   GeneCards; ENPP7; -.
DR   HGNC; HGNC:23764; ENPP7.
DR   HPA; ENSG00000182156; Tissue enriched (intestine).
DR   MalaCards; ENPP7; -.
DR   MIM; 616997; gene.
DR   neXtProt; NX_Q6UWV6; -.
DR   OpenTargets; ENSG00000182156; -.
DR   PharmGKB; PA134986550; -.
DR   VEuPathDB; HostDB:ENSG00000182156; -.
DR   eggNOG; KOG2645; Eukaryota.
DR   GeneTree; ENSGT00940000159339; -.
DR   HOGENOM; CLU_017594_1_0_1; -.
DR   InParanoid; Q6UWV6; -.
DR   OMA; IAHNYKN; -.
DR   OrthoDB; 415411at2759; -.
DR   PAN-GO; Q6UWV6; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; Q6UWV6; -.
DR   TreeFam; TF330032; -.
DR   BRENDA; 3.1.4.12; 2681.
DR   PathwayCommons; Q6UWV6; -.
DR   Reactome; R-HSA-9840310; Glycosphingolipid catabolism.
DR   SignaLink; Q6UWV6; -.
DR   BioGRID-ORCS; 339221; 20 hits in 1149 CRISPR screens.
DR   GeneWiki; ENPP7; -.
DR   GenomeRNAi; 339221; -.
DR   Pharos; Q6UWV6; Tbio.
DR   PRO; PR:Q6UWV6; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q6UWV6; protein.
DR   Bgee; ENSG00000182156; Expressed in jejunal mucosa and 75 other cell types or tissues.
DR   ExpressionAtlas; Q6UWV6; baseline and differential.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0005902; C:microvillus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008081; F:phosphoric diester hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0004767; F:sphingomyelin phosphodiesterase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0046479; P:glycosphingolipid catabolic process; TAS:Reactome.
DR   GO; GO:0044241; P:lipid digestion; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IDA:UniProtKB.
DR   GO; GO:2000304; P:positive regulation of ceramide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0045797; P:positive regulation of intestinal cholesterol absorption; ISS:UniProtKB.
DR   GO; GO:2000755; P:positive regulation of sphingomyelin catabolic process; ISS:UniProtKB.
DR   GO; GO:1904729; P:regulation of intestinal lipid absorption; ISS:UniProtKB.
DR   GO; GO:0006684; P:sphingomyelin metabolic process; IDA:UniProtKB.
DR   CDD; cd16018; Enpp; 1.
DR   FunFam; 3.30.1360.180:FF:000005; ectonucleotide pyrophosphatase/phosphodiesterase family member 7; 1.
DR   FunFam; 3.40.720.10:FF:000048; ectonucleotide pyrophosphatase/phosphodiesterase family member 7; 1.
DR   Gene3D; 3.30.1360.180; -; 1.
DR   Gene3D; 3.40.720.10; Alkaline Phosphatase, subunit A; 1.
DR   InterPro; IPR017850; Alkaline_phosphatase_core_sf.
DR   InterPro; IPR002591; Phosphodiest/P_Trfase.
DR   PANTHER; PTHR10151; ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE; 1.
DR   PANTHER; PTHR10151:SF63; ECTONUCLEOTIDE PYROPHOSPHATASE_PHOSPHODIESTERASE FAMILY MEMBER 7; 1.
DR   Pfam; PF01663; Phosphodiest; 1.
DR   SUPFAM; SSF53649; Alkaline phosphatase-like; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Direct protein sequencing; Glycoprotein;
KW   Hydrolase; Lipid metabolism; Membrane; Metal-binding;
KW   Proteomics identification; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix; Zinc.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:15340161"
FT   CHAIN           22..458
FT                   /note="Ectonucleotide pyrophosphatase/phosphodiesterase
FT                   family member 7"
FT                   /id="PRO_0000036403"
FT   TOPO_DOM        22..433
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        434..454
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        455..458
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REGION          72..78
FT                   /note="Required for enzyme activity"
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   ACT_SITE        75
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000305|PubMed:28292932"
FT   BINDING         39
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   BINDING         75
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   BINDING         96
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD"
FT   BINDING         199
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   BINDING         203
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   BINDING         246
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   BINDING         247
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   BINDING         353
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000305|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   CARBOHYD        100
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15458386,
FT                   ECO:0000269|PubMed:28292932, ECO:0007744|PDB:5TCD,
FT                   ECO:0007744|PDB:5UDY"
FT   CARBOHYD        121
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15458386,
FT                   ECO:0000269|PubMed:28292932, ECO:0007744|PDB:5TCD,
FT                   ECO:0007744|PDB:5UDY"
FT   CARBOHYD        146
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15458386,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:28292932,
FT                   ECO:0007744|PDB:5TCD, ECO:0007744|PDB:5UDY"
FT   CARBOHYD        168
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15458386,
FT                   ECO:0000269|PubMed:28292932, ECO:0007744|PDB:5TCD,
FT                   ECO:0007744|PDB:5UDY"
FT   CARBOHYD        267
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15458386,
FT                   ECO:0000269|PubMed:28292932, ECO:0007744|PDB:5TCD"
FT   VARIANT         4
FT                   /note="P -> L (in dbSNP:rs8074547)"
FT                   /id="VAR_021506"
FT   MUTAGEN         76
FT                   /note="S->F: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   MUTAGEN         78
FT                   /note="C->N: Strongly reduces activity."
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   MUTAGEN         100
FT                   /note="N->Q: Strongly reduces N-glycosylation and enzyme
FT                   activity; when associated with Q-121; Q-146; Q-168 and
FT                   Q-267."
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   MUTAGEN         109
FT                   /note="Y->L: Decreased enzyme activity with sphingomyelin
FT                   and para-nitrophenylphosphorylcholine."
FT                   /evidence="ECO:0000269|PubMed:28292932"
FT   MUTAGEN         121
FT                   /note="N->Q: Strongly reduces N-glycosylation and enzyme
FT                   activity; when associated with Q-100; Q-146; Q-168 and
FT                   Q-267."
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   MUTAGEN         146
FT                   /note="N->Q: Strongly reduces N-glycosylation and enzyme
FT                   activity; when associated with Q-100; Q-146; Q-168 and
FT                   Q-267."
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   MUTAGEN         166
FT                   /note="Y->L: Decreased enzyme activity with sphingomyelin
FT                   and para-nitrophenylphosphorylcholine."
FT                   /evidence="ECO:0000269|PubMed:28292932"
FT   MUTAGEN         168
FT                   /note="N->Q: Strongly reduces N-glycosylation and enzyme
FT                   activity; when associated with Q-100; Q-121; Q-168 and
FT                   Q-267."
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   MUTAGEN         267
FT                   /note="N->Q: Strongly reduces N-glycosylation and enzyme
FT                   activity; when associated with Q-100; Q-121; Q-146 and
FT                   Q-168."
FT                   /evidence="ECO:0000269|PubMed:15458386"
FT   MUTAGEN         271
FT                   /note="R->E: Decreased enzyme activity; when associated
FT                   with E-343."
FT                   /evidence="ECO:0000269|PubMed:28292932"
FT   MUTAGEN         343
FT                   /note="R->E: Decreased enzyme activity; when associated
FT                   with E-271."
FT                   /evidence="ECO:0000269|PubMed:28292932"
FT   MUTAGEN         344..348
FT                   /note="INVQF->ENEQE: Loss of enzyme activity with
FT                   sphingomyelin."
FT                   /evidence="ECO:0000269|PubMed:28292932"
FT   MUTAGEN         344..348
FT                   /note="INVQF->NNNQN: Loss of enzyme activity with
FT                   sphingomyelin."
FT                   /evidence="ECO:0000269|PubMed:28292932"
FT   MUTAGEN         353
FT                   /note="H->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:15016655"
FT   CONFLICT        101
FT                   /note="T -> I (in Ref. 2; AAQ88985)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        388
FT                   /note="Y -> N (in Ref. 3; BAC86504)"
FT                   /evidence="ECO:0000305"
FT   STRAND          32..38
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   TURN            43..48
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           52..60
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          61..65
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           75..84
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           88..91
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          96..100
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   TURN            101..104
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          105..107
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           109..112
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           116..119
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           126..131
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   TURN            132..134
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          137..141
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   TURN            143..146
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          155..158
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           169..185
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          189..195
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           199..205
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           210..232
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   TURN            236..238
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          239..244
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           262..264
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           270..272
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          273..277
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          283..288
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           293..300
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          307..311
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           312..314
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           317..319
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          329..334
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          350..352
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           360..362
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          366..370
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   STRAND          375..379
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           384..386
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           387..395
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           406..408
FT                   /evidence="ECO:0007829|PDB:5TCD"
FT   HELIX           410..412
FT                   /evidence="ECO:0007829|PDB:5TCD"
SQ   SEQUENCE   458 AA;  51478 MW;  A40560D61140F692 CRC64;
     MRGPAVLLTV ALATLLAPGA GAPVQSQGSQ NKLLLVSFDG FRWNYDQDVD TPNLDAMARD
     GVKARYMTPA FVTMTSPCHF TLVTGKYIEN HGVVHNMYYN TTSKVKLPYH ATLGIQRWWD
     NGSVPIWITA QRQGLRAGSF FYPGGNVTYQ GVAVTRSRKE GIAHNYKNET EWRANIDTVM
     AWFTEEDLDL VTLYFGEPDS TGHRYGPESP ERREMVRQVD RTVGYLRESI ARNHLTDRLN
     LIITSDHGMT TVDKRAGDLV EFHKFPNFTF RDIEFELLDY GPNGMLLPKE GRLEKVYDAL
     KDAHPKLHVY KKEAFPEAFH YANNPRVTPL LMYSDLGYVI HGRINVQFNN GEHGFDNKDM
     DMKTIFRAVG PSFRAGLEVE PFESVHVYEL MCRLLGIVPE ANDGHLATLL PMLHTESALP
     PDGRPTLLPK GRSALPPSSR PLLVMGLLGT VILLSEVA
//
